Peter Quarg
Novartis
11 Papers
21 Citations
Peter Quarg is an academic researcher from Novartis. The author has contributed to research in topics: Population & Rivastigmine. The author has an hindex of 5, co-authored 11 publications.
Chat about Author
Papers
Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: results of a meta-analysis.
TL;DR: In this paper, Alzheimer's disease patients experiencing more rapid symptom progression are likely to have a poorer prognosis than those experiencing slow symptom progression, while those experiencing moderate symptom progression have a better prognosis.
A Longitudinal Item Response Theory Model to Characterize Cognition over Time in Elderly Subjects.
Marc Vandemeulebroecke,Björn Bornkamp,Tillmann Krahnke,Johanna Mielke,Andreas U. Monsch,Peter Quarg +5 more
- 01 Sep 2017
TL;DR: A longitudinal Item Response Theory model developed for the Basel Study on the Elderly captured the multifaceted nature of cognition and its longitudinal trajectory, and found greater age at baseline, fewer years of education, and positive APOEɛ4 carrier status were associated with a faster cognitive decline.
17
Umibecestat in the API Generation program: Worsening in RBANS and/or CDR on treatment reverses after wash‐out: Alzheimer’s Prevention Initiative (API) Generation program: Baseline characteristics and umibecestat results during treatment and follow‐up
Ana Graf,Marie-Emmanuelle Riviere,Fonda Liu,Marie-Laure Rouzade-Dominguez,Pilar Cazorla,Matt Quinn,Michal Arkuszewski,Javier Ricart,Jessica B. Langbaum,Hernan Piccard,Yihan Sui,Peter Quarg,Angelika Caputo,Eric M. Reiman,Pierre N. Tariot +14 more
TL;DR: The key clinical results for umibecestat vs placebo during treatment and follow up are summarized.
6
The API Generation program: Umibecestat treatment and discontinuation effects on hippocampal and whole brain volumes in the overall population and amyloid‐negative APOE4 homozygotes: Alzheimer’s Prevention Initiative (API) Generation program: Baseline characteristics and umibecestat results during treatment and follow‐up
Eric M. Reiman,Pierre N. Tariot,Beth Borowsky,Fonda Liu,Marie-Emmanuelle Riviere,Marie-Laure Rouzade-Dominguez,Pilar Cazorla,Matt Quinn,Javier Ricart,Jessica B. Langbaum,Vissia Viglietta,Yihan Sui,Angelika Caputo,Ana Graf,Nicholas Seneca,Ulf Neumann,Udo Eichenlaub,Yuchen Chien,Michal Arkuszewski,Hernan Piccard,Peter Quarg +20 more
TL;DR: Testing the hypotheses that BACE inhibitor‐related hippocampal and whole brain shrinkage is apparent soon after treatment initiation, non‐progressive, limited to A+ participants, and reversible following discontinuation is tested.
6